PROCEPT's Q1 Report May Expose the Gap Between Upgrade and Reality

PROCEPT BioRobotics Corporation (PRCT) reports first-quarter 2026 earnings on April 29, 2026, after market close, with analysts expecting a loss of $0.55 per share on revenue of approximately $80.65 million. The central question is whether the surgical robotics company can reverse the sharp earnings miss from Q4 2025 and demonstrate that its international expansion and Senhance Surgical System adoption are translating into sustainable revenue growth. With the stock trading below all major moving averages and technical signals flashing sell across all timeframes, investors will scrutinize whether management can restore confidence after last quarter's disappointing results.

Part 1: Earnings Preview

PROCEPT BioRobotics Corporation develops and commercializes robotic systems for treating benign prostatic hyperplasia (BPH), with its flagship AquaBeam Robotic System using high-velocity waterjet technology to perform minimally invasive prostate procedures. The company serves urologists across North America and select international markets, positioning itself in the growing surgical robotics sector.

PROCEPT reports Q1 2026 earnings after market close on April 29, 2026. Analysts expect an EPS loss of $0.55 on revenue of $80.65 million. The company most recently reported Q4 2025 results with an actual EPS loss of $0.53, which badly missed the consensus estimate of -$0.32. Compared to the same quarter last year (Q1 2025), when PRCT posted a loss of $0.45 per share, the current estimate of -$0.55 represents a 22.22% deterioration year-over-year, signaling that profitability remains elusive despite revenue growth.

Three key themes define this earnings story:

International Expansion Momentum: PROCEPT's recent partnerships with three UK hospitals and a $25 million EU Horizon 2040 grant have accelerated its European footprint. Investors will watch whether this geographic diversification is driving meaningful procedure volume growth and whether international revenue can offset domestic market saturation concerns. The company's ability to scale the Senhance Surgical System globally is critical to justifying its growth valuation.

Profitability Path Amid Persistent Losses: Despite 12% year-over-year revenue growth in Q4 2025, PROCEPT posted a $29.84 million net loss as R&D and operational expenses remained elevated. Analysts have downgraded EPS estimates significantly over the past 60 days, with the Q1 2026 consensus falling from -$0.31 to -$0.55. The market will scrutinize whether management can demonstrate a credible path to profitability or if continued losses will pressure the stock further.

Restoring Credibility After Q4 Miss: Last quarter's -65.62% earnings surprise was PROCEPT's worst in recent history, breaking a three-quarter streak of beats. The miss raised questions about cost control and operational execution. Analysts will look for management commentary on what went wrong and whether Q1 results can restore confidence in the company's ability to meet guidance.

Heading into the release, Wall Street sentiment is mixed. While seven analysts maintain Strong Buy ratings and the average price target of $30.44 implies 32% upside from current levels, recent estimate revisions have been overwhelmingly negative. Over the past 30 days, eight analysts lowered their Q1 estimates and nine cut their full-year 2026 forecasts, reflecting growing skepticism about near-term profitability. One analyst noted that despite the stock's upgrade to 'Market Outperform' following strong procedure volumes, the company must prove it can scale efficiently without burning excessive cash.

Part 2: Historical Earnings Performance

PROCEPT BioRobotics has demonstrated a mixed but generally positive earnings track record over the past four quarters, though the most recent result represents a significant departure from that pattern. In Q1 2025, the company beat estimates by 8.16%, reporting a loss of $0.45 versus expectations of -$0.49. This was followed by a strong 14.63% beat in Q2 2025 (actual -$0.35 vs. estimate -$0.41) and a 7.32% beat in Q3 2025 (actual -$0.38 vs. estimate -$0.41). This three-quarter streak of consistent outperformance suggested improving operational execution and cost management.

However, Q4 2025 shattered that momentum with a -65.62% miss, as PROCEPT reported a loss of $0.53 against a consensus estimate of just -$0.32. This represents the company's worst earnings surprise in the available history and raises questions about whether the prior beats were sustainable or if Q4 exposed underlying cost pressures that management had previously understated. The magnitude of the miss—more than 65% worse than expected—suggests either a significant one-time expense, deteriorating operational efficiency, or overly optimistic analyst expectations heading into the quarter.

The pattern reveals a company that had been trending toward better-than-expected results but hit a major stumbling block in its most recent report. With Q1 2026 estimates calling for a loss of $0.55—worse than the prior year's Q1 loss of $0.45—analysts appear to be pricing in continued profitability challenges. Investors will watch closely to see whether PROCEPT can return to its earlier pattern of modest beats or if Q4's miss signals a new phase of execution risk.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

PROCEPT BioRobotics typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

PROCEPT's post-earnings price behavior shows significant volatility, with an average absolute Day 0 move of 8.36% and an average Day +1 move of 7.82%. The Day +1 range averages 10.26%, indicating substantial intraday swings as investors digest results and management commentary. Notably, the most recent earnings release on February 25, 2026, saw the stock gain 2.13% on Day 0 but then plunge -15.12% on Day +1—the second-largest Day +1 decline in the dataset—reflecting the market's harsh reaction to the Q4 miss.

Historically, PROCEPT has experienced both explosive upside and sharp downside moves. The October 28, 2024, report produced a remarkable +32.33% Day 0 surge followed by another +6.25% gain on Day +1, demonstrating the stock's potential for dramatic rallies on positive surprises. Conversely, the August 6, 2025, release saw a -5.05% Day 0 drop and a -13.35% Day +1 decline, showing how quickly sentiment can sour. The data suggests investors should prepare for a move in the 8-10% range on average, with the potential for much larger swings depending on whether results and guidance surprise to the upside or downside.

Part 2.2: Options Market Expected Move

The options market is pricing in an expected move of 13.84% through the May 15, 2026, expiration, which is significantly higher than the stock's average historical Day +1 move of 7.82% but closer to the average Day +1 range of 10.26%. This elevated implied volatility of 99.02% suggests options traders are anticipating a larger-than-typical reaction, likely reflecting heightened uncertainty following last quarter's massive miss and the recent deterioration in analyst estimates.

Part 3: What Analysts Are Saying

Analysts maintain a cautiously optimistic stance on PROCEPT BioRobotics, with a consensus rating of 4.00 (Buy) and an average price target of $30.44, implying 32% upside from the current price of $23.03. The rating breakdown shows 7 Strong Buys, 0 Moderate Buys, 5 Holds, 1 Moderate Sell, and 0 Strong Sells among the 13 analysts covering the stock. Price targets range from a low of $20.00 to a high of $37.00, reflecting divergent views on the company's near-term prospects.

Sentiment has remained unchanged over the past month, with the same 7 Strong Buys, 5 Holds, and 1 Moderate Sell as four weeks ago. However, this stability in ratings masks a significant shift in earnings expectations. Over the past 30 days, eight analysts lowered their Q1 2026 EPS estimates and nine cut their full-year 2026 forecasts, indicating growing concern about profitability despite the unchanged rating distribution. The Q1 estimate has deteriorated from -$0.31 sixty days ago to -$0.55 currently, while the full-year 2026 estimate has worsened from -$1.09 to -$1.58 over the same period.

The consensus view appears to be that PROCEPT's long-term growth story remains intact—supported by international expansion, the EU grant, and rising procedure volumes—but near-term profitability is proving more elusive than previously anticipated. The 32% implied upside to the average price target suggests analysts believe the current selloff has created value, but the recent wave of negative estimate revisions indicates that path to profitability may take longer than initially expected. Investors will look for management to provide clearer guidance on when the company expects to reach breakeven and whether the international expansion can accelerate revenue growth enough to offset persistent operating losses.

Part 4: Technical Picture

PROCEPT BioRobotics enters earnings in a technically weak position, with the Barchart Technical Opinion showing a 100% Sell signal, up from 88% Sell both one week and one month ago. This intensifying bearish signal reflects deteriorating momentum as the stock has failed to hold key support levels heading into the release.

Timeframe Analysis:

• Short-term (100% Sell): Strong sell signal indicates near-term momentum is decisively negative, with no bullish technical indicators supporting a bounce
• Medium-term (100% Sell): Sell signal confirms weakness extends beyond just short-term trading, suggesting the intermediate trend has turned bearish
• Long-term (100% Sell): Sell signal reflects sustained weakness in the longer-term trend, indicating the stock's technical foundation has deteriorated significantly

Trend Characteristics: The trend is characterized by Average strength moving in the Strongest direction, suggesting a persistent and accelerating downtrend that shows no signs of stabilization heading into earnings.

The stock is trading at $23.03, below all major moving averages: the 5-day ($24.17), 10-day ($24.67), 20-day ($24.38), 50-day ($25.42), 100-day ($28.60), and 200-day ($33.82). This complete breakdown below all moving averages is a classic sign of a stock in a sustained downtrend, with the 200-day average now serving as significant overhead resistance 32% above current levels.

The technical setup heading into earnings is decidedly cautionary. With the stock trading below all moving averages and technical signals flashing sell across all timeframes, PROCEPT lacks the technical support that would typically cushion a negative earnings surprise. The nearest resistance sits at the 20-day moving average around $24.38, while the 50-day at $25.42 represents a more significant hurdle. On the downside, the stock has limited technical support, making it vulnerable to further declines if results or guidance disappoint. The 13.84% expected move priced into options suggests traders are bracing for significant volatility, and the bearish technical backdrop means any disappointment could trigger an outsized selloff. Conversely, a strong beat and improved guidance could spark a sharp relief rally, though the stock would need to reclaim the 50-day moving average to signal a meaningful trend reversal.